Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study
JCO Global Oncology · 2026-08 · 12 (8)
DOI: 10.1200/go-26-00151 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2026-08. Verfasst von Orhun Akdogan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: Capecitabine, Diclofenac, Hand-Foot Syndrome. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Capecitabine-induced hand-foot syndrome (HFS) is a frequent toxicity that impairs quality of life and may require chemotherapy dose modification. Although prophylactic topical diclofenac showed benefit in a randomized trial, its effectiveness in routine clinical practice remains uncertain. We evaluated the real-world effectiveness of topical diclofenac for prevention of clinically significant capecitabine-induced HFS. METHODS DICLO-HFS was a prospective, two-center observational study conducted in Türkiye between July 2023 and February 2024. Adults with colorectal or gastric cancer receiving capecitabine-based therapy were managed with either prophylactic 1% topical diclofenac twice daily or active monitoring according to routine practice. HFS was assessed weekly using Common Terminology Criteria for Adverse Events v5.0 by physicians not involved in treatment allocation. The primary end point was incidence of grade ≥2 HFS. Secondary end points included time to onset of grade ≥2 HFS and capecitabine dose reductions attributable to HFS. RESULTS A total of 151 patients were included (71 diclofenac; 80 active monitoring). During a median follow-up of 19.1 weeks, grade ≥2 HFS occurred in 12 (16.9%) of 71 patients receiving diclofenac and 11 (13.8%) of 80 patients under active monitoring (odds ratio [OR], 1.28 [95% CI, 0.52 to 3.10]; P = .591). Time to onset did not differ between groups (log-rank P = .392). HFS-related dose reductions occurred in 24 (33.8%) of 71 and 20 (25.0%) of 80 patients, respectively (OR, 1.53 [95% CI, 0.76 to 3.10]; P = .235). In multivariable analysis, female sex and capecitabine monotherapy were independently associated with grade ≥2 HFS. CONCLUSION In this prospective real-world study, prophylactic topical diclofenac did not reduce clinically significant capecitabine-induced HFS or delay its onset compared with active monitoring. These findings do not support routine diclofenac prophylaxis in everyday practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey.
- Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey.
ORCID-Profile: Orhun Akdogan, Sevgi Eryildiz Yucel, Galip Can Uyar, Enes Yesilbas, Kadriye Baskurt, Ahmet Ozet, Nuriye Ozdemir, Osman Sutcuoglu
Zitieren
APA
Akdogan, O., Yucel, S. E., Yazici, O., Yucel, K. B., Gurler, F., Uyar, G. C., Savas, G., Yesilbas, E., Coskun, U., Baskurt, K., Uner, A., Ozet, A., Oksuzoglu, B., Ozdemir, N., & Sutcuoglu, O. (2026). Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study. JCO Global Oncology, 12(8). https://doi.org/10.1200/go-26-00151
Vancouver
Akdogan O, Yucel SE, Yazici O, Yucel KB, Gurler F, Uyar GC, et al. Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study. JCO Global Oncology. 2026;12(8). doi:10.1200/go-26-00151
BibTeX
@article{Akdogan2026,
author = {Akdogan, Orhun and Yucel, Sevgi Eryildiz and Yazici, Ozan and Yucel, Kadriye Bir and Gurler, Fatih and Uyar, Galip Can and Savas, Gözde and Yesilbas, Enes and Coskun, Ugur and Baskurt, Kadriye and Uner, Aytug and Ozet, Ahmet and Oksuzoglu, Berna and Ozdemir, Nuriye and Sutcuoglu, Osman},
title = {Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study},
journal = {JCO Global Oncology},
year = {2026},
volume = {12},
number = {8},
doi = {10.1200/go-26-00151}
}
EUVIMED